Samsara BioCapital’s SpringWorks Therapeutics SWTX Stock Holding History

Samsara BioCapital’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-22,204	Closed	-$578K	–	58
2022 Q4	$578K	Hold	22,204	–	–	0.12%	42
2022 Q3	$633K	Hold	22,204	–	–	0.15%	45
2022 Q2	$547K	Sell	22,204 -37,000	-62%	-$1.35M	0.15%	48
2022 Q1	$3.34M	Sell	59,204 -81,063	-58%	-$4.64M	0.84%	30
2021 Q4	$8.69M	Sell	140,267 -29,585	-17%	-$1.96M	1.69%	15
2021 Q3	$10.8M	Hold	169,852	–	–	1.69%	15
2021 Q2	$14M	Hold	169,852	–	–	1.73%	12
2021 Q1	$12.5M	Sell	169,852 -92,720	-35%	-$7.26M	2.3%	13
2020 Q4	$19K	Sell	262,572 -135,445	-34%	-$8.72M	1.91%	8
2020 Q3	$19M	Sell	398,017 -159,339	-29%	-$6.79M	5.29%	4
2020 Q2	$23.4M	Sell	557,356 -67,925	-11%	-$2.42M	7.53%	2
2020 Q1	$16.9M	Sell	625,281 -28,221	-4%	-$920K	9.72%	3
2019 Q4	$25.2M	Sell	653,502 -23,100	-3%	-$541K	12.05%	2
2019 Q3	$14.7M	Buy	+676,602	New	+$16M	9.98%	4

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Samsara BioCapital's SWTX Position: Q1 2023 in Review

Samsara BioCapital sold out of SpringWorks Therapeutics (SWTX) in Q1 2023, closing a stake of 22,204 shares — an estimated $578K sold.

Samsara BioCapital first reported a position in SWTX in Q3 2019 and held it in 14 quarters. The position peaked at $25.2M in Q4 2019. 148 funds tracked by Wall St. Rank hold SWTX as of Q1 2023.

Samsara BioCapital reported no remaining SpringWorks Therapeutics position as of Q1 2023 after selling out during the quarter.
Samsara BioCapital sold 22,204 SpringWorks Therapeutics shares in Q1 2023, an estimated $578K.
Samsara BioCapital first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 14 quarters.
Samsara BioCapital's SpringWorks Therapeutics position peaked at $25.2M in Q4 2019.
148 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2023.

Based on Samsara BioCapital's 13F filing for Q1 2023, filed 15 May 2023.